

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT	DISEASE Bile duct adenocarcinoma	PHYSICIAN	ORDERING PHYSICIAN Yeh, Yi-Chen	SPECIMEN	SPECIMEN ID YLY 12/27/1950
	NAME Yu, Yen-Ling		MEDICAL FACILITY Taipei Veterans General Hospital		SPECIMEN TYPE Blood
	DATE OF BIRTH 27 December 1950		ADDITIONAL RECIPIENT None		DATE OF COLLECTION 24 January 2022
	SEX Female		MEDICAL FACILITY ID 205872		SPECIMEN RECEIVED 28 January 2022
	MEDICAL RECORD # 10033199		PATHOLOGIST Not Provided		

Biomarker Findings

Blood Tumor Mutational Burden - 1 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Elevated Tumor Fraction Not Detected

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

PIK3CA E545K
DNMT3A E240fs*72

† See About the Test in appendix for details.

Report Highlights

- Targeted therapies with potential clinical benefit approved in another tumor type: Everolimus (p. 6), Temsirolimus (p. 6)
- Evidence-matched clinical trial options based on this patient's genomic findings: (p. 8)
- Variants that may represent clonal hematopoiesis and may originate from non-tumor sources: **DNMT3A** E240fs*72 (p. 5)

BIOMARKER FINDINGS

Blood Tumor Mutational Burden - 1 Muts/Mb

Microsatellite status - MSI-High Not Detected

Tumor Fraction - Elevated Tumor Fraction Not Detected

GENOMIC FINDINGS

PIK3CA - E545K 0.17%

10 Trials see p. 8

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. See Biomarker Findings section

MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).

Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected. The fact that elevated tumor fraction was not detected in this specimen indicates the possibility of lower levels of ctDNA but does not compromise confidence in any reported alterations. However, in the setting of a negative liquid biopsy result, orthogonal testing of a tissue specimen should be considered if clinically indicated (see Biomarker Findings section).

THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)

None

THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)

Everolimus

Temsirolimus

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS (CH)

Genomic findings below may include nontumor somatic alterations, such as CH. The efficacy of targeting such nontumor somatic alterations is unknown. This content should be interpreted based on clinical context. Refer to appendix for additional information on CH.

DNMT3A - E240fs*72 p. 5

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. • 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS


For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

DNMT3A - E240fs*72 p. 5

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of APC, ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MEN1, MLH1, MSH2, MSH6, MUTYH, NF1, NF2, PALB2, PMS2, POLE, PTEN, RAD51C, RAD51D, RB1, RET, SDHA, SDHB, SDHC, SDHD, SMAD4, STK11, TGFBR2, TP53, TSC1, TSC2, VHL, and WT1 is recommended.

Variant Allele Frequency is not applicable for copy number alterations.

ORDERED TEST # ORD-1289646-01



HISTORIC PATIENT FINDINGS		ORD-1289646-01 VAF%
Blood Tumor Mutational Burden		1 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		Elevated Tumor Fraction Not Detected
PIK3CA	● E545K	0.17%
DNMT3A	● E240fs*72	0.57%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx, FoundationOne®Liquid, FoundationOne®, or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of $\geq 5\%$, and bTMB is calculated based on variants with an allele frequency of $\geq 0.5\%$.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

VAF% = variant allele frequency percentage

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

BIOMARKER FINDINGS

BIOMARKER

Blood Tumor Mutational Burden

RESULT

1 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1¹⁻² and anti-PD-1³ therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb¹. In HNSCC, a Phase 3 trial showed

that bTMB ≥ 16 Muts/Mb (approximate equivalency ≥ 8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor⁴.

FREQUENCY & PROGNOSIS

Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)⁵⁻⁷. Published data investigating the prognostic implications of bTMB levels in biliary tract cancer are limited (PubMed, Jul 2021). Although cases with hypermutated biliary tract cancer were enriched in a subgroup with poor prognosis in 1 study⁸, TMB-high (≥ 10 mut/Mb) status in biliary adenocarcinoma not treated with immunotherapy was not significantly associated with OS in another study, in which patients with TMB-high tumors experienced numerically longer OS compared with patients with TMB-low tumors (11.5 vs. 8.4 months, adjusted HR=0.65)⁹.

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma¹⁰⁻¹¹ and cigarette smoke in lung cancer¹²⁻¹³, treatment with temozolomide-based chemotherapy in glioma¹⁴⁻¹⁵, mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes¹⁶⁻²⁰, and microsatellite instability (MSI)^{16,19-20}. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents¹⁻³. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

BIOMARKER

Tumor Fraction

RESULT

Elevated Tumor Fraction Not Detected

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Specimens with elevated tumor fraction values have high circulating-tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not

be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management²¹⁻²⁶.

FREQUENCY & PROGNOSIS

Detectable ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)²⁷. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer²⁸, Ewing sarcoma and osteosarcoma²⁹, prostate cancer²⁴, breast cancer³⁰, leiomyosarcoma³¹, esophageal cancer³², colorectal

cancer³³, and gastrointestinal cancer³⁴.

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content³⁵, the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy³⁶⁻³⁷.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. • 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

GENOMIC FINDINGS
GENE

PIK3CA

ALTERATION

E545K

TRANSCRIPT ID

NM_006218

CODING SEQUENCE EFFECT

1633G>A

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —

Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K³⁸⁻⁴⁰, AKT⁴¹⁻⁴², or mTOR⁴³⁻⁵⁰. In the Phase 2 MATCH trial for patients with PIK3CA-mutated solid tumors, 28% (18/65) of patients experienced PFS lasting at least 6 months after treatment with

taselisib; however, no ORs were observed in this study⁵¹. A separate Phase 1b study of taselisib in combination with the CDK4/6 inhibitor palbociclib for patients with PIK3CA-mutated solid tumors reported an ORR of 0% (n=12) and a DCR of 17% (2/12)⁵². In a Phase 1 trial of the dual PI3K/mTOR kinase inhibitor apitolisib, 79% (11/14) of patients with PIK3CA-mutated advanced solid tumors experienced disease control (3 PRs, 8 SDs)⁵³. The PI3K inhibitor alpelisib demonstrated an ORR of 6.0% (8/134) and a DCR of 58% (78/134) in a study for patients with PIK3CA-mutated solid tumors⁵⁴. However, the PI3K inhibitor copanlisib exhibited limited efficacy in PIK3CA-mutated tumors⁵⁵⁻⁵⁶.

FREQUENCY & PROGNOSIS

PIK3CA mutations have been reported in 0-6% of intrahepatic cholangiocarcinoma cases and in 4-13% of gallbladder carcinoma cases⁵⁷⁻⁶², although one study of Chinese patients with

cholangiocarcinoma reported PIK3CA mutations in 32% of tumors⁶³. PIK3CA mutations appear to be more common in intraductal papillary mucinous neoplasm/carcinoma while rarely observed in the more common and aggressive ductal adenocarcinoma of the pancreas⁶⁴⁻⁶⁹. Published data investigating the prognostic implications of PIK3CA alterations in biliary tract carcinoma are limited (PubMed, Jul 2021).

FINDING SUMMARY

PIK3CA encodes p110-alpha, which is the catalytic subunit of phosphatidylinositol 3-kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival⁷⁰⁻⁷¹. PIK3CA alterations that have been characterized as activating, such as observed here, are predicted to be oncogenic⁷²⁻⁹².

GENE

DNMT3A

ALTERATION

E240fs*72

TRANSCRIPT ID

NM_022552

CODING SEQUENCE EFFECT

717_729delGGAGGAGGCCAGC

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors.

FREQUENCY & PROGNOSIS

DNMT3A alterations have been reported at

relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2022)⁵⁻⁶. Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2022).

FINDING SUMMARY

The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation⁹³⁻⁹⁴. The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor⁹⁵⁻¹⁰⁰. Alterations such as seen here may disrupt DNMT3A function or expression¹⁰¹⁻¹⁰⁴.

POTENTIAL CLONAL HEMATOPOIESIS
IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion¹⁰⁵⁻¹¹⁰. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy¹⁰⁵⁻¹⁰⁶. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease¹¹¹. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH^{109,112-113}. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

THERAPIES WITH CLINICAL BENEFIT

IN OTHER TUMOR TYPE

Everolimus

Assay findings association

PIK3CA
E545K

AREAS OF THERAPEUTIC USE

Everolimus is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors; and well-differentiated non-functional neuroendocrine tumors of the lung or gastrointestinal tract. Everolimus is also approved to treat either renal angiomyolipoma or subependymal giant cell astrocytoma in association with tuberous sclerosis complex (TSC). Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence⁴³⁻⁵⁰, PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0-4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25-44%), for patients with PIK3CA-mutated solid tumors^{47-50,114-118}.

SUPPORTING DATA

Of 2 patients with PIK3CA-mutated advanced biliary tract cancer included in the Phase 2 RADiChol study, 1 experienced prolonged PFS of 16.7 months with everolimus¹¹⁹. Case studies have reported additional

patients with PIK3CA-mutated gallbladder carcinoma or cholangiocarcinoma who benefited from everolimus treatment¹²⁰⁻¹²¹. A Phase 2 study of everolimus in patients with advanced biliary tract cancer showed 2.6% (1/38) PR and 42.1% (16/38) SD, and a median PFS of 3.2 months¹²². Another Phase 2 study of everolimus in patients with biliary tract cancer reported 7.4% (2/27) PR, 48.1% (13/27) SD, and a median PFS of 6 months¹²³. An observational study of everolimus in biliary tract cancer reported a disease control rate of 50%, but a high incidence (64%) of severe toxicities in patients with biliary tract cancer¹²⁴. A Phase 1 trial of everolimus combined with sorafenib reported SD >10 weeks in 62% of cholangiocarcinoma patients¹²⁵. A Phase 1 trial evaluating everolimus in combination with gemcitabine and/or cisplatin for the treatment of patients with solid tumors reported 0% PR, 60% SD, and 40% PD in an expansion cohort of 10 patients with cholangiocarcinoma or gallbladder carcinoma¹²⁶. Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors¹²⁷, a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months¹²⁸.

Temsirolimus

Assay findings association

PIK3CA
E545K

AREAS OF THERAPEUTIC USE

Temsirolimus is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence⁴³⁻⁵⁰, PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0-4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25-44%), for patients with PIK3CA-mutated solid tumors^{47-50,114-118}.

SUPPORTING DATA

Clinical data on the efficacy of temsirolimus for the treatment of biliary tract cancers are limited (PubMed, Jan 2022). A Phase 1 trial of bevacizumab and temsirolimus

plus liposomal doxorubicin in patients with advanced solid tumors showed that the combination was well tolerated and resulted in six-month SD in 21% of patients, with a 21% rate of partial or complete remission⁴⁸. In a Phase 2 clinical trial in non-small cell lung cancer (NSCLC), temsirolimus showed clinical benefit, but further studies are warranted¹²⁹. A Phase 2 study of temsirolimus in patients with KRAS-mutant colorectal cancer reported limited efficacy; however, all patients who exhibited tumor reduction were found to have low levels of mutated KRAS in plasma samples¹³⁰. A Phase 2 clinical trial in patients with pancreatic cancer reported that temsirolimus monotherapy had limited efficacy, and may have contributed to disease progression¹³¹. A study examining the efficacy of temsirolimus-involving regimens in 24 patients with mesenchymal/metaplastic breast cancer (MpBCs) reported 2 CRs, 4 PRs, 2 instances of SD longer than 6 months, and 4 instances of SD shorter than 6 months¹¹⁷.

NOTE Genomic alterations detected may be associated with activity of certain US FDA or other specific country approved therapies; however, the therapies listed in this report may have varied evidence in the patient's tumor type. The listed therapies are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. The therapies listed in this report may not be complete and/or exhaustive. Furthermore, the

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. • 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

THERAPIES WITH CLINICAL BENEFIT
IN OTHER TUMOR TYPE

listed therapies are limited to US FDA approved pharmaceutical drug products that are linked to a specific genomic alteration. There may also be US FDA approved pharmaceutical drug products that are not linked to a genomic alteration. Further there may also exist pharmaceutical drug products that are not approved by the US FDA or other national authorities. There may also be other treatment modalities available than pharmaceutical drug products.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

CLINICAL TRIALS

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or

research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or

in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

GENE
PIK3CA
ALTERATION
 E545K

RATIONALE
 PIK3CA activating mutations may lead to activation of the PI3K-AKT-mTOR pathway and may therefore indicate sensitivity to inhibitors of

this pathway. Strong clinical data support sensitivity of PIK3CA-mutated solid tumors to the PI3K-alpha inhibitor alpelisib.

NCT04589845
PHASE 2

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

TARGETS

TRKB, ALK, TRKC, ROS1, TRKA, RET, PD-L1, AKTs, ERBB2, MDM2, PI3K-alpha

LOCATIONS: Zhongzheng Dist. (Taiwan), Taipei City (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Beijing (China), Woolloongabba (Australia), Darlinghurst (Australia), Randwick (Australia), Melbourne (Australia), Haifa (Israel)

NCT03239015
PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS

EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT03768375
PHASE 2

Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

TARGETS

EGFR, mTOR, ERBB2

LOCATIONS: Shanghai (China)

NCT02688881
PHASE 4

Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors

TARGETS

mTOR

LOCATIONS: Seoul (Korea, Republic of)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. • 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

CLINICAL TRIALS
NCT04803318
PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
 mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT03772561
PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
 PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

NCT04801966
PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
 CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT03994796
PHASE 2

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

TARGETS
 TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR

LOCATIONS: Alaska, Washington

NCT04632992
PHASE 2

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

TARGETS
 TRKB, ALK, TRKC, ROS1, TRKA, PD-L1, ERBB2, PI3K-alpha, RET, AKTs

LOCATIONS: Alaska, Washington, Oregon, California, Montana

NCT03297606
PHASE 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

TARGETS
 VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO

LOCATIONS: Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

 Electronically signed by Douglas Lin, M.D. | 04 February 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. · 1.888.988.3639

 Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

APPENDIX
Variants of Unknown Significance

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

ALK
V163L and V867I

DDR1
V208M

MLH1
R217C

MLL2
Q4254R

NOTCH1
Q1134R

NOTCH2
S220R

NSD3 (WHSC1L1)
D679G

XRCC2
V39M

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

APPENDIX
Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 Exons 4-9	ACVR1B	AKT1 Exon 3	AKT2	AKT3	ALK Exons 20-29, Introns 18, 19	ALOX12B	AMER1 (FAM123B)	APC
AR	ARAF Exons 4, 5, 7, 11, 13, 15, 16	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX	AURKA
AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2	BCL6
BCOR	BCORL1	BCR* Introns 8, 13, 14	BRAF Exons 11-18, Introns 7-10	BRCA1 Introns 2, 7, 8, 12, 16, 19, 20	BRCA2 Intron 2	BRD4	BRIP1	BTG1
BTG2	BTK Exons 2, 15	C11orf30 (EMSY)	C17orf39 (GID4)	CALR	CARD11	CASP8	CBFB	CBL
CCND1	CCND2	CCND3	CCNE1	CD22	CD70	CD74* Introns 6-8	CD79A	CD79B
CD274 (PD-L1)	CDC73	CDH1	CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B
CDKN2A	CDKN2B	CDKN2C	CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL
CSF1R	CSF3R	CTCF	CTNNA1	CTNNB1 Exon 3	CUL3	CUL4A	CXCR4	CYP17A1
DAXX	DDR1	DDR2 Exons 5, 17, 18	DIS3	DNMT3A	DOT1L	EED	EGFR Introns 7, 15, 24-27	EP300
EPHA3	EPHB1	EPHB4	ERBB2	ERBB3 Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25	ERBB4	ERCC4	ERG	ERRFI1
ESR1 Exons 4-8	ETV4* Intron 8	ETV5* Introns 6, 7	ETV6* Introns 5, 6	EWSR1* Introns 7-13	EZH2 Exons 4, 16, 17, 18	EZR* Introns 9-11	FAM46C	FANCA
FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12	FGF14	FGF19
FGF23	FGF3	FGF4	FGF6	FGFR1 Introns 1, 5, Intron 17	FGFR2 Intron 1, Intron 17	FGFR3 Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17	FGFR4	FH
FLCN	FLT1	FLT3 Exons 14, 15, 20	FOXL2	FUBP1	GABRA6	GATA3	GATA4	GATA6
GNA11 Exons 4, 5	GNA13	GNAQ Exons 4, 5	GNAS Exons 1, 8	GRM3	GSK3B	H3F3A	HDAC1	HGF
HNFI1A	HRAS Exons 2, 3	HSD3B1	ID3	IDH1 Exon 4	IDH2 Exon 4	IGF1R	IKBKE	IKZF1
INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2 Exon 14	JAK3 Exons 5, 11, 12, 13, 15, 16	JUN	KDM5A
KDM5C	KDM6A	KDR	KEAP1	KEL	KIT Exons 8, 9, 11, 12, 13, 17, Intron 16	KLHL6	KMT2A (MLL) Introns 6, 8-11, Intron 7	KMT2D (MLL2)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

APPENDIX
Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

KRAS	LTK	LYN	MAF	MAP2K1 (MEK1) Exons 2, 3	MAP2K2 (MEK2) Exons 2-4, 6, 7	MAP2K4	MAP3K1	MAP3K13
MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MERTK	MET
MITF	MKNK1	MLH1	MPL Exon 10	MRE11A	MSH2 Intron 5	MSH3	MSH6	MST1R
MTAP	MTOR Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56	MUTYH	MYB* Intron 14	MYC Intron 1	MYCL (MYCL1)	MYCN	MYD88 Exon 4	NBN
NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2 Intron 26	NOTCH3	NPM1 Exons 4-6, 8, 10
NRAS Exons 2, 3	NSD3 (WHSC1L1)	NTSC2	NTRK1 Exons 14, 15, Introns 8-11	NTRK2 Intron 12	NTRK3 Exons 16, 17	NUTM1* Intron 1	P2RY8	PALB2
PARK2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)	PDGFRA Exons 12, 18, Introns 7, 9, 11
PDGFRB Exons 12-21, 23	PDK1	PIK3C2B	PIK3C2G	PIK3CA Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20) PPP2R2A	PIK3CB	PIK3R1	PIM1	PMS2
POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI	PTCH1
PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51	RAD51B	RAD51C
RAD51D	RAD52	RAD54L	RAF1 Exons 3, 4, 6, 7, 10, 14, 15, 17, Introns 4-8	RARA Intron 2	RB1	RBM10	REL	RET Introns 7, 8, Exons 11, 13-16, Introns 9-11
RICTOR	RNF43	ROS1 Exons 31, 36-38, 40, Introns 31-35	RPTOR	RSP02* Intron 1	SDC4* Intron 2	SDHA	SDHB	SDHC
SDHD	SETD2	SF3B1	SGK1	SLC34A2* Intron 4	SMAD2	SMAD4	SMARCA4	SMARCB1
SMO	SNCAIP	SOC1	SOX2	SOX9	SPEN	SPOP	SRC	STAG2
STAT3	STK11	SUFU	SYK	TBX3	TEK	TERC* ncRNA	TERT* Promoter	TET2
TGFBR2	TIPARP	TMPRSS2* Introns 1-3	TNFAIP3	TNFRSF14	TP53	TSC1	TSC2	TYRO3
U2AF1	VEGFA	VHL	WHSC1	WT1	XPO1	XRCC2	ZNF217	ZNF703

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status

Blood Tumor Mutational Burden (bTMB)

Tumor Fraction

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

APPENDIX

About FoundationOne® Liquid CDx

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.



ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted

cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also reports tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF THERAPIES AND CLINICAL TRIALS

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of $\geq 5\%$, and bTMB is calculated based on variants with an allele frequency of $\geq 0.5\%$.
8. Tumor fraction is the percentage of circulating tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from the observed level of aneuploidy in the sample. Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected and is significantly distinct from that typically found in non-tumor samples.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

APPENDIX

About FoundationOne® Liquid CDx

to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, *TP53*, and *U2AF1*.

11. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.
12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *PALB2*, *PMS2*, *POLE*, *RAD51C*, *RAD51D*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *TSC2*, and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to

distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *IDH2*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. • 1.888.988.3639

© 2022 Foundation Medicine, Inc. All rights reserved.
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

APPENDIX

About FoundationOne®Liquid CDx

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.2.0

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1289646-01

APPENDIX
References

1. Gandara DR, et al. Nat. Med. (2018) PMID: 30082870
2. Wang Z, et al. JAMA Oncol (2019) PMID: 30816954
3. Aggarwal C, et al. Clin. Cancer Res. (2020) PMID: 32102950
4. Li et al., 2020; ASCO Abstract 6511
5. Cerami E, et al. Cancer Discov (2012) PMID: 22588877
6. Gao J, et al. Sci Signal (2013) PMID: 23550210
7. Tate JG, et al. Nucleic Acids Res. (2019) PMID: 30371878
8. Nakamura H, et al. Nat. Genet. (2015) PMID: 26258846
9. Shao C, et al. JAMA Netw Open (2020) PMID: 33119110
10. Pfeifer GP, et al. Mutat. Res. (2005) PMID: 15748635
11. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) PMID: 23875803
12. Pfeifer GP, et al. Oncogene (2002) PMID: 12379884
13. Rizvi NA, et al. Science (2015) PMID: 25765070
14. Johnson BE, et al. Science (2014) PMID: 24336570
15. Choi S, et al. Neuro-oncology (2018) PMID: 29452419
16. Cancer Genome Atlas Research Network, et al. Nature (2013) PMID: 23636398
17. Briggs S, et al. J. Pathol. (2013) PMID: 23447401
18. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) PMID: 24583393
19. Nature (2012) PMID: 22810696
20. Roberts SA, et al. Nat. Rev. Cancer (2014) PMID: 25568919
21. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) PMID: 30923679
22. Raja R, et al. Clin. Cancer Res. (2018) PMID: 30093454
23. Hrebien S, et al. Ann. Oncol. (2019) PMID: 30860573
24. Choudhury AD, et al. JCI Insight (2018) PMID: 30385733
25. Goodall J, et al. Cancer Discov (2017) PMID: 28450425
26. Goldberg SB, et al. Clin. Cancer Res. (2018) PMID: 29330207
27. Bettgowda C, et al. Sci Transl Med (2014) PMID: 24553385
28. Lapin M, et al. J Transl Med (2018) PMID: 30400802
29. Shulman DS, et al. Br. J. Cancer (2018) PMID: 30131550
30. Stover DG, et al. J. Clin. Oncol. (2018) PMID: 29298117
31. Hemming ML, et al. JCO Precis Oncol (2019) PMID: 30793095
32. Egyud M, et al. Ann. Thorac. Surg. (2019) PMID: 31059681
33. Fan G, et al. PLoS ONE (2017) PMID: 28187169
34. Vu et al., 2020; DOI: 10.1200/PO.19.00204
35. Li G, et al. J Gastrointest Oncol (2019) PMID: 31602320
36. Zhang EW, et al. Cancer (2020) PMID: 32757294
37. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) PMID: 30833418
38. Fritsch C, et al. Mol. Cancer Ther. (2014) PMID: 24608574
39. Juric D, et al. J. Clin. Oncol. (2018) PMID: 29401002
40. Gallant JN, et al. NPJ Precis Oncol (2019) PMID: 30793038
41. André F, et al. N. Engl. J. Med. (2019) PMID: 31091374
42. Smyth LM, et al. NPJ Breast Cancer (2021) PMID: 33863913
43. Park HS, et al. PLoS ONE (2016) PMID: 27105424
44. Lim SM, et al. Oncotarget (2016) PMID: 26859683
45. Hou MM, et al. Oncotarget (2014) PMID: 25426553
46. Varnier R, et al. Eur J Cancer (2019) PMID: 31351267
47. Janku F, et al. Cell Rep (2014) PMID: 24440717
48. Moroney J, et al. Clin. Cancer Res. (2012) PMID: 22927482
49. Basho RK, et al. JAMA Oncol (2017) PMID: 27893038
50. Moroney JW, et al. Clin. Cancer Res. (2011) PMID: 21890452
51. Krop et al., 2018; ASCO Abstract 101
52. Pascual J, et al. Cancer Discov (2021) PMID: 32958578
53. Dolly SO, et al. Clin. Cancer Res. (2016) PMID: 26787751
54. Aust Fam Physician (1986) PMID: 2941002
55. Santin AD, et al. Gynecol Oncol Rep (2020) PMID: 31934607
56. Patnaik A, et al. Ann. Oncol. (2016) PMID: 27672108
57. Riener MO, et al. Genes Chromosomes Cancer (2008) PMID: 18181165
58. Deshpande V, et al. BMC Cancer (2011) PMID: 21303542
59. Borger DR, et al. Oncologist (2012) PMID: 22180306
60. Jang S, et al. Mod. Pathol. (2014) PMID: 24186137
61. Voss JS, et al. Hum. Pathol. (2013) PMID: 23391413
62. Ross JS, et al. Oncologist (2014) PMID: 24563076
63. Xu RF, et al. Biomed. Pharmacother. (2011) PMID: 21051183
64. Schönleben F, et al. Langenbecks Arch Surg (2008) PMID: 18343945
65. Yamaguchi H, et al. Am. J. Surg. Pathol. (2011) PMID: 21945955
66. Schönleben F, et al. Clin. Cancer Res. (2006) PMID: 16778113
67. Xiao HD, et al. J. Pathol. (2011) PMID: 21547907
68. Kuboki Y, et al. Mod. Pathol. (2010) PMID: 20495538
69. Schönleben F, et al. J. Gastrointest. Surg. (2009) PMID: 19440799
70. Samuels Y, et al. Cancer Cell (2005) PMID: 15950905
71. Nat. Rev. Cancer (2009) PMID: 19629070
72. Kang S, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) PMID: 15647370
73. Ikenoue T, et al. Cancer Res. (2005) PMID: 15930273
74. Gymnopoulos M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) PMID: 17376864
75. Horn S, et al. Oncogene (2008) PMID: 18317450
76. Rudd ML, et al. Clin. Cancer Res. (2011) PMID: 21266528
77. Hon WC, et al. Oncogene (2012) PMID: 22120714
78. Burke JE, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) PMID: 22949682
79. Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) PMID: 19915146
80. Lauretti R, et al. Rev Saude Publica (1990) PMID: 2103068
81. Dan S, et al. Cancer Res. (2010) PMID: 20530683
82. Oda K, et al. Cancer Res. (2008) PMID: 18829572
83. Zhao L, et al. Oncogene (2008) PMID: 18794883
84. Lui VW, et al. Cancer Discov (2013) PMID: 23619167
85. Ross RL, et al. Oncogene (2013) PMID: 22430209
86. Rivière JB, et al. Nat. Genet. (2012) PMID: 22729224
87. Shibata T, et al. Cancer Lett. (2009) PMID: 19394761
88. Dogruluk T, et al. Cancer Res. (2015) PMID: 26627007
89. Croessmann S, et al. Clin. Cancer Res. (2018) PMID: 29284706
90. Ng PK, et al. Cancer Cell (2018) PMID: 29533785
91. Spangle JM, et al. (2020) PMID: 32929011
92. Chen L, et al. Nat Commun (2018) PMID: 29636477
93. Trowbridge JJ, et al. Nat. Genet. (2011) PMID: 22200773
94. Prog Mol Biol Transl Sci (2011) PMID: 21507354
95. Yang J, et al. Mol Med Rep (2011) PMID: 21887466
96. Vallböhmer D, et al. Clin Lung Cancer (2006) PMID: 16870044
97. Daskalos A, et al. Cancer (2011) PMID: 21351083
98. Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) PMID: 17890317
99. Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) PMID: 22011581
100. Kim MS, et al. APMIS (2013) PMID: 23031157
101. Chen ZX, et al. J. Cell. Biochem. (2005) PMID: 15861382
102. Guo X, et al. Nature (2015) PMID: 25383530
103. Sandoval JE, et al. J. Biol. Chem. (2019) PMID: 30705090
104. Zhang ZM, et al. Nature (2018) PMID: 29414941
105. Jaiswal S, et al. N. Engl. J. Med. (2014) PMID: 25426837
106. Genovese G, et al. N. Engl. J. Med. (2014) PMID: 25426838
107. Xie M, et al. Nat. Med. (2014) PMID: 25326804
108. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) PMID: 28669404
109. Severson EA, et al. Blood (2018) PMID: 29678827
110. Fuster JJ, et al. Circ. Res. (2018) PMID: 29420212
111. Hematology Am Soc Hematol Educ Program (2018) PMID: 30504320
112. Chabon JJ, et al. Nature (2020) PMID: 32269342
113. Razavi P, et al. Nat. Med. (2019) PMID: 31768066
114. Janku F, et al. Cancer Res. (2013) PMID: 23066039
115. Janku F, et al. J. Clin. Oncol. (2012) PMID: 22271473
116. Janku F, et al. Mol. Cancer Ther. (2011) PMID: 21216929
117. Moulder S, et al. Ann. Oncol. (2015) PMID: 25878190
118. Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07
119. Lau DK, et al. Br J Cancer (2018) PMID: 29527009
120. Feng F, et al. Oncol Rep (2020) PMID: 32323774
121. Bian JL, et al. World J Gastroenterol (2017) PMID: 28694672
122. Buzzoni R, et al. Ann. Oncol. (2014) PMID: 24827133
123. Yeung et al., 2014; ASCO Abstract 4101
124. Verzoni E, et al. Future Oncol (2014) PMID: 25145431
125. You et al., 2016; ASCO Abstract 2532
126. Costello BA, et al. Invest New Drugs (2014) PMID: 24740268
127. Tolcher AW, et al. Ann. Oncol. (2015) PMID: 25344362
128. Patterson et al., 2018; AACR Abstract 3891
129. Reungwetwattana T, et al. J Thorac Oncol (2012) PMID: 22722792
130. Spindler KL, et al. Acta Oncol (2013) PMID: 23514584
131. Javle MM, et al. BMC Cancer (2010) PMID: 20630061

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Douglas Lin, M.D. | 04 February 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. • 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531